AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced positive results from its multicenter, randomized controlled PermeaDerm-I clinical study on August 18, 2026. The data demonstrates that PermeaDerm, a biosynthetic wound matrix, provides clinically comparable outcomes to cadaveric allograft while offering a significant economic advantage for hospitals treating acute wounds.

The study met its primary endpoint, showing statistically significant superiority (p<0.001) for mean cost per percent total body surface area (%TBSA) treated. Mean treatment cost was $148.70 for every 1% TBSA treated with PermeaDerm compared with $497.10 for allograft. This represents a savings of approximately $348 per %TBSA, equating to a 70% reduction in product cost.

What the Numbers Show

The cost differential is driven by both unit pricing and operational efficiency. While the per-unit cost difference accounts for the majority of the savings, the elimination of preparation steps further enhances the economic profile. PermeaDerm reduced preparation time by 95.7% compared with allograft by eliminating tissue tracking, thawing, and meshing requirements. This operational simplification allows for off-the-shelf availability without compromising application time in the operating room.

Clinical outcomes remained comparable between treatment groups. Approximately 94% of PermeaDerm patients achieved at least 95% graft take one week following autografting, matching allograft performance. All patients in both groups achieved 95% or greater wound healing by eight weeks. No adverse events were attributed to PermeaDerm during the study.

The randomized controlled study enrolled 40 patients across 11 U.S. burn centers with wounds involving up to 30% TBSA. Following excision, patients were randomized to receive either PermeaDerm or cadaveric allograft during the temporization period before definitive split-thickness skin grafting. At final follow-up, all responding investigators and patients reported satisfaction, with responses rated as satisfied or very satisfied.

"Temporary wound coverage is a critical step between excision and definitive closure when a wound bed is not yet ready for autograft placement," said Anju Saraswat, MD, Associate Burn Director and Assistant Professor of Surgery at Atrium Health Wake Forest Baptist Burn Center and study investigator. "These results demonstrate that PermeaDerm provided clinical performance comparable to allograft with the added benefit of product transparency enabling direct visualization of the wound bed."

Cary Vance, President and Chief Executive Officer of AVITA Medical, stated that the study establishes compelling clinical and economic evidence supporting PermeaDerm as a modern alternative to allograft. He noted that combining comparable clinical performance with meaningful economic value and a simpler workflow addresses an important need for hospitals while strengthening the company’s differentiated acute wound care portfolio.

AVITA Medical will host a Key Opinion Leader webinar featuring Dr. Anju Saraswat and Dr. Christina Sharon, Burn and Acute Care Surgeon at Baton Rouge General, to review the clinical data. The event is scheduled for Tuesday, August 18, 2026, at 4:30 p.m. Eastern Time.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) has scheduled an investor webinar briefing for August 12, 2026, to provide shareholders and prospective investors with an update on its recent financial performance. The event serves as a direct engagement platform for the company’s leadership team to discuss operational outcomes and address investor inquiries regarding the therapeutic acute wound care firm’s trajectory.

The webinar is set to begin at 4:00 p.m. Pacific Time on August 12, 2026, which corresponds to 9:00 a.m. Australian Eastern Standard Time on August 13, 2026. Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, will lead the presentation. The session will focus on the financial and business results reported during AVITA Medical’s recent second-quarter 2026 earnings webcast, ensuring that investors have access to detailed commentary beyond the initial earnings release.

Event Details and Registration

Participants are invited to register for the virtual event via the company’s designated Zoom link. Questions from attendees can be submitted through the registration page prior to the live session. A replay of the webinar will be made available on AVITA Medical’s investor relations website following the conclusion of the live broadcast, allowing those unable to attend in real time to review the material.

Business Overview

AVITA Medical operates as a leading therapeutic acute wound care company, delivering solutions designed to optimize wound healing and accelerate patient recovery. Its flagship technology, RECELL, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of thermal burn and trauma wounds. RECELL utilizes a patient’s own skin cells to create Spray-On Skin, offering an innovative point-of-care solution.

In the United States, AVITA Medical holds exclusive rights to market, sell, and distribute Cohealyx, a collagen-based dermal matrix, as well as PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL and RECELL GO hold CE marks in Europe, TGA certification in Australia, Medsafe listing in New Zealand, and PMDA approval in Japan, reflecting the company’s broad regulatory footprint across key global markets.